Fiducient Advisors’s ResMed RMD Stock Holding History

Fiducient Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,584	Closed	-$332K	–	75
2022 Q2	$332K	Buy	+1,584	New	+$337K	0.12%	61
2021 Q4	–	Sell	-963	Closed	-$254K	–	93
2021 Q3	$254K	Sell	963 -100	-9%	-$27.3K	0.08%	87
2021 Q2	$262K	Hold	1,063	–	–	0.08%	69
2021 Q1	$206K	Hold	1,063	–	–	0.07%	80
2020 Q4	$226K	Buy	+1,063	New	+$212K	0.08%	71

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Fiducient Advisors's RMD Position: Q3 2022 in Review

Fiducient Advisors sold out of ResMed (RMD) in Q3 2022, closing a stake of 1,584 shares — an estimated $332K sold.

Fiducient Advisors first reported a position in RMD in Q4 2020 and held it in 5 quarters. The position peaked at $332K in Q2 2022. 667 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

Fiducient Advisors reported no remaining ResMed position as of Q3 2022 after selling out during the quarter.
Fiducient Advisors sold 1,584 ResMed shares in Q3 2022, an estimated $332K.
Fiducient Advisors first reported a position in ResMed in Q4 2020 and held it in 5 quarters.
Fiducient Advisors's ResMed position peaked at $332K in Q2 2022.
667 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on Fiducient Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.